Ljubljana/summary
From 2007.igem.org
Line 70: | Line 70: | ||
- | <h3><span>Prospects for | + | <h3><span>Prospects for future work and real world applications</span></h3> |
<p class="p1"> | <p class="p1"> | ||
Line 76: | Line 76: | ||
<ul> | <ul> | ||
<li>The idea of relying on viral functions could be applied also to other HIV-specific processes (such as genome integration, reverse transcription…). | <li>The idea of relying on viral functions could be applied also to other HIV-specific processes (such as genome integration, reverse transcription…). | ||
- | <li>Our system based on <a href="https://2007.igem.org/Ljubljana/biobricks">BioBricks</a> has been useful | + | <li>Our system based on <a href="https://2007.igem.org/Ljubljana/biobricks">BioBricks</a> has been useful to prove the principle, but for the real application cellular delivery would be much better applied using vectors based on viral delivery. |
- | <li>In case of using viral vectors therapy could be delivered specifically to the relevant cells that can be infected by HIV-1 (e.g. similar as T-cell-directed retroviral delivery systems described by David Baltimore at SB2.0). | + | <li>In the case of using viral vectors, therapy could be delivered specifically to the relevant cells that can be infected by HIV-1 (e.g. similar as T-cell-directed retroviral delivery systems described by David Baltimore at SB2.0). |
<li>Selection of different effectors will (and can) be made based on further experiments – apoptosis can only be used in 100% leak-proof systems, while antiviral and immune response effectors are not as sensitive. | <li>Selection of different effectors will (and can) be made based on further experiments – apoptosis can only be used in 100% leak-proof systems, while antiviral and immune response effectors are not as sensitive. | ||
- | <li>Similar systems can be prepared for therapy of many other pathogens, particularly viruses (e.g. yellow | + | <li>Similar systems can be prepared for therapy of many other pathogens, particularly viruses (e.g. yellow fever, SARS, foot and mouth disease…) which contain specific proteases and rely on defined cellular receptors. |
</ul> | </ul> | ||
Revision as of 13:40, 26 October 2007
Achievements
Prospects for future work and real world applications
- The idea of relying on viral functions could be applied also to other HIV-specific processes (such as genome integration, reverse transcription…).
- Our system based on BioBricks has been useful to prove the principle, but for the real application cellular delivery would be much better applied using vectors based on viral delivery.
- In the case of using viral vectors, therapy could be delivered specifically to the relevant cells that can be infected by HIV-1 (e.g. similar as T-cell-directed retroviral delivery systems described by David Baltimore at SB2.0).
- Selection of different effectors will (and can) be made based on further experiments – apoptosis can only be used in 100% leak-proof systems, while antiviral and immune response effectors are not as sensitive.
- Similar systems can be prepared for therapy of many other pathogens, particularly viruses (e.g. yellow fever, SARS, foot and mouth disease…) which contain specific proteases and rely on defined cellular receptors.